THERAMEX Trademark

Trademark Overview


On Thursday, September 8, 2022, a trademark application was filed for THERAMEX with the United States Patent and Trademark Office. The USPTO has given the THERAMEX trademark a serial number of 97583075. The federal status of this trademark filing is REGISTERED as of Tuesday, December 5, 2023. This trademark is owned by Theramex HQ UK Limited. The THERAMEX trademark is filed in the Pharmaceutical Products category with the following description:

Anti-fungal pharmaceutical preparations; Contraceptive preparations; contraceptive sponges; chemical contraceptives; oral contraceptives; Dermatological pharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations and substances for use in relation to women's health, namely, menopause, osteoporosis, uterine fibroids, endometriosis, adenomyosis, menstrual bleeding disorders, fertility, infertility, assisted reproductive technology, IVF; Pharmaceutical preparations and substances containing steroids; Pharmaceutical preparations and substances containing hormones; Pharmaceutical preparations and substances in the nature of hormone replacement therapy; pharmaceutical preparations and substances for use in relation to reproductive health, namely, contraception, menstrual bleeding disorders, fertility, infertility, fertility enhancement preparations, assisted reproductive technology, IVF, miscarriage; pharmaceutical preparations and substances for us...
theramex

General Information


Serial Number97583075
Word MarkTHERAMEX
Filing DateThursday, September 8, 2022
Status700 - REGISTERED
Status DateTuesday, December 5, 2023
Registration Number7233958
Registration DateTuesday, December 5, 2023
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 19, 2023

Trademark Statements


Goods and ServicesAnti-fungal pharmaceutical preparations; Contraceptive preparations; contraceptive sponges; chemical contraceptives; oral contraceptives; Dermatological pharmaceutical preparations; Diagnostic preparations for medical purposes; Pharmaceutical preparations and substances for use in relation to women's health, namely, menopause, osteoporosis, uterine fibroids, endometriosis, adenomyosis, menstrual bleeding disorders, fertility, infertility, assisted reproductive technology, IVF; Pharmaceutical preparations and substances containing steroids; Pharmaceutical preparations and substances containing hormones; Pharmaceutical preparations and substances in the nature of hormone replacement therapy; pharmaceutical preparations and substances for use in relation to reproductive health, namely, contraception, menstrual bleeding disorders, fertility, infertility, fertility enhancement preparations, assisted reproductive technology, IVF, miscarriage; pharmaceutical preparations and substances for use in relation to contraception; pharmaceutical preparations and substances for use in relation to conception, namely, contraception, menstrual bleeding disorders, fertility, infertility, fertility enhancement preparations, assisted reproductive technology, IVF, miscarriage; pharmaceutical preparations and substances for use in relation to fertility; fertility enhancement preparations; pharmaceutical preparations and substances for use in relation to the treatment of infertility; pharmaceutical preparations and substances for use in endocrinology; pharmaceutical preparations and substances for use in gynaecology; pharmaceutical preparations and substances for use in rheumatology; pharmaceutical preparations and substances for use in dermatology; Pharmaceutical preparations for the treatment of menopause; Pharmaceutical preparations and substances for the alleviation of menopause-related symptoms; Pharmaceutical preparations and substances for the treatment of osteoporosis; Pharmaceutical preparations and substances for the alleviation of osteoporosis-related symptoms; Pharmaceutical preparations and substances for the treatment of cartilage disorders; Pharmaceutical preparations and substances for the treatment of bone disorders; Pharmaceutical preparations and substances for the treatment of bone loss; Pharmaceutical preparations and substances for the treatment of arthritis; Pharmaceutical preparations and substances for the treatment of calcium deficiency; Pharmaceutical preparations and substances being calcium regulators; Pharmaceutical preparations and substances for the treatment of Paget's disease; Phosphates for pharmaceutical purposes; Self-injectors sold filled with pharmaceutical preparations for the treatment of infertility for subcutaneous injection, osteoporosis; Vitamin supplements; mineral supplements; calcium supplements; all the above being for human use and none being for dental use or for use in relation to oral hygiene

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateMonday, September 26, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTheramex HQ UK Limited
Party Type30 - Original Registrant
Legal Entity Type99 - Other
AddressBelgravia, London SW1W8NS
GB

Party NameTheramex HQ UK Limited
Party Type20 - Owner at Publication
Legal Entity Type99 - Other
AddressBelgravia, London SW1W8NS
GB

Party NameTheramex HQ UK Limited
Party Type10 - Original Applicant
Legal Entity Type99 - Other
AddressBelgravia, London SW1W8NS
GB

Trademark Events


Event DateEvent Description
Tuesday, December 5, 2023NOTICE OF REGISTRATION CONFIRMATION EMAILED
Tuesday, December 5, 2023REGISTERED-PRINCIPAL REGISTER
Thursday, September 21, 2023WITHDRAWN FROM ISSUE - PETITIONS OFFICE REQUEST
Wednesday, September 20, 2023TEAS DELETE 1(B) BASIS RECEIVED
Tuesday, September 19, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 19, 2023PUBLISHED FOR OPPOSITION
Wednesday, August 30, 2023NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Monday, August 14, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, August 11, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, August 11, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, August 11, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, July 6, 2023NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, July 6, 2023NON-FINAL ACTION E-MAILED
Thursday, July 6, 2023NON-FINAL ACTION WRITTEN
Thursday, June 22, 2023ASSIGNED TO EXAMINER
Monday, September 26, 2022NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Monday, September 12, 2022NEW APPLICATION ENTERED